Related Experiment Video

Updated: Aug 18, 2026

Quantification of Colonic Stem Cell Mutations
07:53

Quantification of Colonic Stem Cell Mutations

Published on: September 25, 2015

Frequency of glucose-6-phosphate dehydrogenase deficiency in some ethnic groups of Pakistan

Nadir Ali1, Masood Anwar, Mohammad Ayyub

  • 1Department of Pathology, Combined Military Hospital, Attock, Pakistan. nmjrm@hotmail.com

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|April 6, 2005
PubMed

Insights

Glucose-6-phosphate dehydrogenase (G6PD) deficiency was found in 1.8% of young Pakistani males. This study screened 3000 healthy males, noting variations across ethnic groups.

Area of Science:

  • Medical Genetics
  • Hematology
  • Public Health

Background:

  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited red blood cell disorder.
  • Understanding its prevalence in specific populations is crucial for public health initiatives.

Purpose of the Study:

  • To determine the frequency of G6PD deficiency in young, healthy adult males.
  • To analyze the prevalence across different ethnic groups in Pakistan.

Main Methods:

  • A descriptive study was conducted involving 3000 healthy adult males aged 17-23 years.
  • The Met-hemoglobin reduction test was used for G6PD screening.
  • Clinical data, including ethnic group and medical history, were recorded.

Main Results:

  • G6PD deficiency was detected in 1.8% of the screened population.
  • Prevalence varied among ethnic groups: 1.07% in Kashmiris, 1.47% in Punjabis, 2.77% in Sindhis, and 3.17% in Pathans.
  • A history of recurrent jaundice was noted in 5.7% and mild anemia in 3.8% of participants.

Conclusions:

  • The overall frequency of G6PD deficiency in young healthy Pakistani males is 1.8%.
  • A statistically insignificant difference in G6PD deficiency was observed among most ethnic groups, with a notable exception in Pathans.
Abstract

More Related Videos

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism07:59

Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism

Published on: August 19, 2021

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Other Glycolytic Pathways01:24

Other Glycolytic Pathways

The pentose phosphate pathway (PPP) operates in parallel with glycolysis, facilitating the metabolism of both pentoses and glucose. This pathway consists of two distinct phases: the oxidative and non-oxidative phases. While it does not directly generate ATP, the intermediates formed during the process can integrate into glycolysis, contributing to cellular energy metabolism when required.Oxidative Phase: NADPH ProductionThe oxidative phase of the pentose phosphate pathway is primarily...